| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |